These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28274401)

  • 21. Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate.
    Schultheiss TE; Hanks GE; Hunt MA; Lee WR
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):643-9. PubMed ID: 7790250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anatomy-based inverse planning dose optimization in HDR prostate implant: a toxicity study.
    Mahmoudieh A; Tremblay C; Beaulieu L; Lachance B; Harel F; Lessard E; Pouliot J; Vigneault E
    Radiother Oncol; 2005 Jun; 75(3):318-24. PubMed ID: 16086913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer.
    Ghadjar P; Matzinger O; Isaak B; Behrensmeier F; Stroux A; Rentsch CA; Thalmann GN; Aebersold DM
    Radiother Oncol; 2009 May; 91(2):237-42. PubMed ID: 19167121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer.
    Nath SK; Sandhu AP; Rose BS; Simpson DR; Nobiensky PD; Wang JZ; Millard F; Kane CJ; Parsons JK; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):435-41. PubMed ID: 19939580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Late genitourinary toxicity in salvage radiotherapy for prostate cancer after radical prostatectomy: impact of daily fraction doses.
    Takano S; Tomita N; Takaoka T; Niwa M; Torii A; Kita N; Okazaki D; Uchiyama K; Nakanishi-Imai M; Ayakawa S; Iida M; Tsuzuki Y; Otsuka S; Manabe Y; Nomura K; Ogawa Y; Miyakawa A; Miyamoto A; Takemoto S; Yasui T; Hiwatashi A
    Br J Radiol; 2024 May; 97(1157):1050-1056. PubMed ID: 38466928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
    Herrera FG; Valerio M; Berthold D; Tawadros T; Meuwly JY; Vallet V; Baumgartner P; Thierry AC; De Bari B; Jichlinski P; Kandalaft L; Coukos G; Harari A; Bourhis J
    Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):320-334. PubMed ID: 30267761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxicity at 1 Year After Stereotactic Body Radiation Therapy in 3 Fractions for Localized Prostate Cancer.
    Magli A; Farneti A; Faiella A; Ferriero M; Landoni V; Giannarelli D; Moretti E; de Paula U; Gomellini S; Sanguineti G
    Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):93-100. PubMed ID: 33745951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer.
    Jawad MS; Dilworth JT; Gustafson GS; Ye H; Wallace M; Martinez A; Chen PY; Krauss DJ
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):657-66. PubMed ID: 26797541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
    Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
    Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereotactic Body Radiation Therapy to the Prostate Bed: Results of a Phase 1 Dose-Escalation Trial.
    Sampath S; Frankel P; Vecchio BD; Ruel N; Yuh B; Liu A; Tsai T; Wong J
    Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):537-545. PubMed ID: 31733323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results.
    Madsen BL; Hsi RA; Pham HT; Fowler JF; Esagui L; Corman J
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1099-105. PubMed ID: 17336216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity.
    Karlsdóttir A; Muren LP; Wentzel-Larsen T; Dahl O
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1478-86. PubMed ID: 18060703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Interfractional Bladder and Trigone Displacement and Deformation on Radiation Exposure and Subsequent Acute Genitourinary Toxicity: A Post Hoc Analysis of Patients Treated with Magnetic Resonance Imaging-Guided Prostate Stereotactic Body Radiation Therapy in a Phase 3 Randomized Trial.
    Neilsen BK; Ma TM; Akingbemi WO; Neylon J; Casado MC; Sharma S; Sheng K; Ruan D; Low DA; Yang Y; Valle LF; Steinberg ML; Lamb JM; Cao M; Kishan AU
    Int J Radiat Oncol Biol Phys; 2024 Mar; 118(4):986-997. PubMed ID: 37871887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer.
    Liauw SL; Weichselbaum RR; Rash C; Correa D; Al-Hallaq HA; Pelizzari CA; Jani AB
    Technol Cancer Res Treat; 2009 Jun; 8(3):201-6. PubMed ID: 19445537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints.
    Peters M; van der Voort van Zyp J; Hoekstra C; Westendorp H; van de Pol S; Moerland M; Maenhout M; Kattevilder R; van Vulpen M
    Radiother Oncol; 2015 Nov; 117(2):262-9. PubMed ID: 26349590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase 1 Trial of Focal Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer.
    Patel KR; Rydzewski NR; Schott E; Cooley-Zgela T; Ning H; Cheng J; Salerno K; Huang EP; Pinto PA; Lindenberg L; Mena E; Choyke P; Turkbey B; Citrin DE
    Pract Radiat Oncol; 2023; 13(6):540-550. PubMed ID: 37442430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
    Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.
    Kittel JA; Reddy CA; Smith KL; Stephans KL; Tendulkar RD; Ulchaker J; Angermeier K; Campbell S; Stephenson A; Klein EA; Wilkinson DA; Ciezki JP
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):884-93. PubMed ID: 25962627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.